Investigational Drug Information for Obicetrapib
✉ Email this page to a colleague
What is the drug development status for Obicetrapib?
Obicetrapib is an investigational drug.
There have been 8 clinical trials for Obicetrapib.
The most recent clinical trial was a Phase 2 trial, which was initiated on February 1st 2022.
The most common disease conditions in clinical trials are Hypercholesterolemia, Dyslipidemias, and Hyperlipoproteinemia Type II. The leading clinical trial sponsors are NewAmsterdam Pharma and [disabled in preview].
There are three US patents protecting this investigational drug and eighty-nine international patents.
Summary for Obicetrapib
US Patents | 3 |
International Patents | 89 |
US Patent Applications | 20 |
WIPO Patent Applications | 15 |
Japanese Patent Applications | 3 |
Clinical Trial Progress | Phase 2 (2022-02-01) |
Vendors | 14 |
Recent Clinical Trials for Obicetrapib
Title | Sponsor | Phase |
---|---|---|
Randomized Study in Patients With HeFH to Evaluate Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies | NewAmsterdam Pharma | Phase 3 |
A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy. | NewAmsterdam Pharma | Phase 2 |
Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy | NewAmsterdam Pharma | Phase 2 |
Clinical Trial Summary for Obicetrapib
Top disease conditions for Obicetrapib
Top clinical trial sponsors for Obicetrapib
US Patents for Obicetrapib
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
Obicetrapib | ⤷ Try a Trial | Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives | DEZIMA PHARMA B.V. (Naarden, NL) | ⤷ Try a Trial |
Obicetrapib | ⤷ Try a Trial | Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and HMG CoA reductase inhibitors | DEZIMA PHARMA B.V. (NL) | ⤷ Try a Trial |
Obicetrapib | ⤷ Try a Trial | Cholesteryl ester transfer protein (CETP) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases | DEZIMA PHARMA BV (NL) | ⤷ Try a Trial |
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Obicetrapib
Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
---|---|---|---|---|
Obicetrapib | Argentina | AR101509 | 2034-08-12 | ⤷ Try a Trial |
Obicetrapib | Australia | AU2015302407 | 2034-08-12 | ⤷ Try a Trial |
Obicetrapib | Brazil | BR112017002873 | 2034-08-12 | ⤷ Try a Trial |
>Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |